Jacobs Levy Equity Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Jacobs Levy Equity Management’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$739K	Buy	+57,943	New	+$748K	﹤0.01%	765
2016 Q4	–	Hold	0	–	-$72K	–	1051
2016 Q3	–	Hold	0	–	–	–	977
2016 Q2	–	Hold	0	–	–	–	1006
2016 Q1	–	Hold	0	–	–	–	879

Other funds holding TNXP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JHC

Jones Hill Capital New York $470M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Ishara Investments Los Angeles, California $136M AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jacobs Levy Equity Management's TNXP Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Tonix Pharmaceuticals (TNXP) in Q2 2026: 57,943 shares worth $739K. The stake represents ﹤0.01% of the portfolio and ranks #765 among its holdings.

103 funds tracked by Wall St. Rank hold TNXP as of Q2 2026.

Jacobs Levy Equity Management held 57,943 shares of Tonix Pharmaceuticals worth $739K as of Q2 2026.
Tonix Pharmaceuticals was a new Jacobs Levy Equity Management position in Q2 2026.
Tonix Pharmaceuticals made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #765 holding.
103 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.